medication being called Zertane has the active ingredient tramadol hydrochloride. Tramadol hydrochloride has been used since the mid-1990’s for pain relief and is being repositioned as a premature ejaculation drug.
It is estimated that about 23% of men between ages 18-75 experience premature ejaculation.
The medication which was tested in Europe showed some significant results during trials in Europe. The drug would be taken as needed.
The data collected from the trial is expected to allow Ampio Pharmaceuticals to apply for European regulatory approval for the drug. No mention of plans to market the drug in the US has been stated.